Feature | Radiation Therapy | October 21, 2016 | Dave Fornell

FDA: Discontinue Use of Multidata Systems International Corp. Radiation Therapy Devices

Company has continued to produce, sell and service non-FDA cleared devices for radiation therapy

Multidata Systems International Corp, water phantom, FDA warning

October 21, 2016 — The U.S. Food and Drug Administration (FDA) issued a letter calling on radiation oncologists, medical physicists, dosimetrists and radiation therapists to stop using all medical devices manufactured and sold by Multidata Systems International Corp. The FDA said it is concerned about the risks to patients from the use of devices, which never received FDA market clearance. 

William Maisel, M.D., MPH, deputy for the Center Director for Science, Center for Devices and Radiological Health, FDA, said the agency knows of at least two Multidata medical devices that the company manufactured and distributed in the United States for which FDA never received nor reviewed 510(k) premarket notifications. These devices include: (1) accessories to radiation therapy devices including the Real Time Dosimetry (RTD) Waterphantom System; and (2) the Dual Channel Electrometer. In addition, Multidata has not registered or listed their devices with the FDA, as required by federal law.

Since 2003, Multidata has been under a Consent Decree of Permanent Injunction entered by the U.S. District Court for the Eastern District of Missouri (civil action no. 4:03cv575). Maisel said the decree prohibits Multidata from designing, manufacturing, processing, and distributing medical devices, among other restrictions. The FDA has learned, however, that Multidata manufactured and distributed medical devices in violation of the decree, including repairing and exchanging waterphantom devices for newer design models.

“The FDA is concerned that healthcare providers may be unaware of the risks associated with these devices and urges facilities to discontinue the use of any devices manufactured by Multidata,” Maisel said. He explained these need to be dispose of appropriately and replaced with accessories to radiation therapy devices and radiation treatment planning software that have been reviewed and cleared by FDA.

Analysis of the Problem

At this time, it is not known how many devices manufactured by Multidata are currently in use in hospitals and clinics throughout the United States. The FDA is not aware of adverse event reports associated with the use of Multidata's devices since Multidata has been under the decree, but because the FDA has not received or reviewed 510(k) premarket notifications, the agency is concerned about the potential risk to patients from the devices.

FDA Recommendations

In a letter to providers, Maisel urged discontinuing the use of any devices manufactured by Multidata and disposal of them appropriately. The FDA urges use of accessories to radiation therapy devices and radiation treatment planning software that have been cleared by the FDA. Registered manufacturers of these types of devices are listed under the IYE product code in the FDA’s Registration and Listing Database (www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm).

Maisel also said centers should follow quality assurance procedures to verify treatment plans by independent means, which may include manual calculations or measurements of radiation doses.

FDA Actions

Through inspections, the FDA learned that Multidata was designing, manufacturing, processing and distributing medical devices in violation of the decree. As a result, on March 3, 2016, the FDA sent a letter to Multidata ordering the firm to cease designing, manufacturing, processing, packing, repacking, labeling, installing, holding for sale and distributing any medical device. The company has now permanently ceased operations and will be dissolving.

The FDA will keep the public informed if significant new information becomes available, Maisel said. 

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology. Most popular radiology articles and news in January 2019.

The top article from January was about researchers in Sweden using computed tomography (CT) to image the soft tissue of an ancient Egyptian mummy’s hand down to a microscopic level. Non-destructive imaging of human and animal mummies with X-rays and CT has been a boon to the fields of archaeology and paleopathology.

Feature | February 01, 2019 | A.J. Connell and Dave Fornell
February 1, 2019 — Here is the list of the most popular content on the Imaging Technology News (ITN) magazine website
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof